Submission of Annual Report of Goldline Pharmaceutical Limited for FY 2025-26.

To Date: 06/08/2026 The Manager Corporate Relationship Department, BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai - 400001. Scrip Code: 544759, Scrip ID: GLPL, Sub: Submission of Annual Report. Sir / Ma’am, Pursuant to Regulation 34 (1) of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015, we are submitting herewith the Annual Report of Company for the Financial Year 2025-26, including Notice convening 22nd Annual General Meeting (AGM) of members of the company scheduled to be held on Saturday, 29th August, 2026 at 04:00 P.M. at Hotel Airport Centre Point, 131/1, Adjacent to Airport, Wardha Road, Somalwada, Nagpur, Maharashtra 440025 which was sent in electronic mode to the Members. The Annual Report for the Financial Year 2025-26 is also available at the Company’s website https://www.goldlinepharma.in/AnnualReports.html For your information and record. Kindly acknowledge and oblige Thanking you, Yours faithfully, FOR GOLDLINE PHARMACEUTICAL LIMITED Ruchi Sanket Modi Company Secretary cum Compliance Officer COMPANY’S PROFILE Goldline Pharmaceutical Limited is the fastest growing pharmaceutical company, operating in states in India (Maharashtra, Chhattisgarh, Madhya Pradesh, Orissa, Tamil Nadu, Rajasthan, Jharkhand, Goa & Bihar) with over 20 years of experience focusing on quality therapeutic brands and customer satisfaction: Goldline pharmaceutical Limited is the fastest growing Pharmaceutical Company, operating in states in India. (Maharashtra, Chhattisgarh, Madhya Pradesh, Orissa, Tamil Nadu, Rajasthan, Jharkhand, Goa & Bihar) We are EXPANDING with full swing in coming months, day by day. It is mandatory for us to match our business inventory to the business generation year by year. Every achievement, every earned riche and every incredible success has a beginning and that beginning lies in an idea. An idea that dawned 20 years back by a visionary Mr. Amol Mujumdar, a pharmacy graduate with a stint of pharma marketing experience that he needed to give shape to his vision of entrepreneurship in pharmaceutical business and carved out a reckoning niche in the domain. He drew a simple line and plated it with gold. That was the beginning of a great happening. Goldline pharmaceutical Limited was born on 28 February 2005 and nurtured with care, commitment, determination and perseverance. The entity gestated on indelible commitments, set values and aims to take firm roots into its own soil at Nagpur. Soon the only to stem out and exponentially firm up into a strengthening trunk with healthy branches and leaves, reaching out far and wide with enriching credentials offering such quality of therapeutic brands that have gold standard finesse in their hearts. Its people naturally hold high the organization’s unflinching culture of rock-solid trusteeship with heart touching customer delights. Mr. Swapan Khandelwal joined the Company in 2010 at a crucial stage of its growth and has since played a significant role in strengthening its foundation. His extensive expertise in building and managing distribution networks, coupled with his sound financial acumen, has been instrumental in streamlining operations and driving sustainable growth. His strategic guidance and unwavering commitment have created long-term value for the Company and have contributed meaningfully to its successful journey. Goldline Pharmaceutical Limited since inception is operating on basics of marketing principles. That does not indicate that they are rigid and not in accordance with the changing necessities and dynamics of market. A strong intelligent marketing and product management team work with perfect coordination with an equally efficient and effective field force striving to deliver all inputs that generate market share with a positive growth. OUR PRODUCTS GOLDLINE PHARMA: This category includes 42 products designed to cater to specialties such as Physicians, Orthopedics, ENT, Chest Physicians, General and Specialty Surgery, Gastroenterology, Neurology, and Urology. One example is our product ACE 15, which contains Serratiopeptidase. Serratiopeptidase is known for its key role in reducing pain and inflammation by inhibiting the release of chemical messengers responsible for pain and fever. The Pharma Division includes a diversified multi-specialty outpatient portfolio aligned with routine prescribing patterns across general medicine and allied specialties. GOLDLINE CARDINAL: This category comprises 54 products tailored for the Specialty division, serving medical fields such as Physicians, Diabetologists, Endocrinologists, Cardiologists, and General Physicians. One example is our product METORIGHTAM, which contains Metoprolol 25mg ER and Amlodipine 5mg. This prescription medication is used to treat high blood pressure, angina (chest pain), and certain heart rhythm disorders. It combines two drugs that work synergistically to lower blood pressure effectively. The Cardinal Division caters to cardio-diabetic therapies for chronic lifestyle diseases such as cardiovascular disorders and diabetes, requiring long-term treatment and continuous care. GOLDLINE AAYUSHMAN: This category comprises 18 products designed for the Specialty division, catering to medical fields such as Pediatricians, Child Specialists, Neonatologists, and General Practitioners. An example of our product in this category is ELSIE, which contains a combination of Doxylamine, Pyridoxine (Vitamin B6), and Folic Acid. This combination is commonly used to treat nausea and vomiting associated with pregnancy. The Aayushman Division focuses on gynaecology and paediatric products to address specialised healthcare needs of women and children through targeted therapeutic offerings. GOLDLINE IN LIFE: This category includes 22 products tailored for the Specialty division, serving Intensivists, Critical Care Consultants, Super Specialty Surgeons, and Physicians. One example is our product ECOPIP 4.5, which contains a combination of Piperacillin and Tazobactam. This injectable combination is used to treat bacterial infections in various parts of the body, such as the stomach, bowel, lungs, skin, and female reproductive organs. The InLife Division comprises injectable and critical care products primarily used in hospital and ICU settings for acute and emergency care. GOLDLINE WELLNESS: This category includes 10 products tailored Supportive care plays a crucial role in cancer therapy, aiming to enhance the quality of life while patients endure the challenges of the disease. It is essential to provide comprehensive care that goes beyond treatment, offering continuous support throughout their journey. The Wellness range of products is designed to do just that—going beyond treatment and beyond support. Goldline Wellness is a specialized range of products crafted for cancer warriors and survivors, helping to improve survival rates and strengthen the body's disease-fighting abilities. By addressing the holistic well- being of patients, these products contribute to a better, healthier life during and after cancer treatment. The Wellness Division focuses on supportive and adjunct therapies, including oncology supportive care products, aimed at improving treatment tolerance and quality of life. AWARDS & RECOGNITION Initial Public Offering (IPO) & Listing The Financial Year 2025–26 marked a significant milestone in the Company's journey with the successful completion of its Initial Public Offering (IPO). Pursuant to the IPO, the equity shares of Goldline Pharmaceutical Limited were listed on the BSE SME Platform on May 19, 2026, marking the Company's entry into the capital markets and reinforcing its commitment to transparency, good governance, and sustainable growth. The Board expresses its sincere gratitude to all shareholders, investors, bankers, intermediaries, regulators, and other stakeholders for their trust and continued support. CORPORATE INFORMATION BOARD OF DIRE [Showing first 8,000 characters — download PDF for full document]